Skip to content

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis 1

A Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. This study is currently recruiting participants. Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis. Clinical Research Trial: Psoriasis and Psoriatic Disorders, New York, Clinical Research Trial: Psoriasis and Psoriatic Disorders, New York, NY on CenterWatch Clinical Trial Listing Service. Research Study Summary A Phase 3, Multicenter, Double-blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the treatment of Plaque Psoriasis.

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis 2Alternative Names: Halobetasol propionate/tazarotene; IDP-118; Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis. This study has been completed. Sponsor: Valeant Pharmaceuticals International, Inc. 302 Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis. This study is not yet open for participant recruitment. (see Contacts and Locations).

Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis ClinicalTrials. Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis (Valeant Pharmaceuticals International, Inc.) View Original at ClinicalTrials.gov. Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Conditions: Plaque Psoriasis Purpose: This is a double-blind study to evaluate the safety and efficacy of topical IDP-118 Lotion when applied once daily to adult subjects with moderate to severe plaque psoriasis.

Scibites

Clinical Trial: 301 Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis. US Fed News Service, Including US State News. Options for topical treatment of psoriasis continue to expand with the development of products featuring novel vehicles or new molecules. A phosphodiesterase-4 inhibitor (AN2728, Anacor Pharmaceuticals) is also in development as a topical treatment for plaque psoriasis and for atopic dermatitis. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris a randomized phase III study (PSO-FAST). Novel Psoriasis Therapies and Patient Outcomes, Part 1: Topical Medications. The use of combination treatments of mid to highly potent corticosteroids and tazarotene has shown enhanced tolerability and therapeutic efficacy. Another phase 2 trial evaluating the efficacy and safety of IDP-118 lotion (HP 0. The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans.

Scibites